Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study
<p><strong>Objective:</strong> Levels of chitotriosidase (CHIT1) are increased in the cerebrospinal fluid (CSF) of amyotrophic lateral sclerosis (ALS) patients reflecting microglial activation. Here, we determine the diagnostic and prognostic potential of CHIT1 for early symptomati...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Taylor and Francis
2021
|
_version_ | 1797061859864477696 |
---|---|
author | Steinacker, P Feneberg, E Halbgebauer, S Witzel, S Verde, F Oeckl, P Van Damme, P Gaur, N Gray, E Grosskreutz, J Jardel, CG Kachanov, M Kuhle, J Lamari, F Maceski, A del Mar Amador, M Mayer, B Morelli, C Petri, S Poesen, K Raaphorst, J Salachas, F Silani, V Turner, M Verbeek, MM Volk, AE Weishaupt, JH Weydt, P Ludolph, AC Otto, M |
author_facet | Steinacker, P Feneberg, E Halbgebauer, S Witzel, S Verde, F Oeckl, P Van Damme, P Gaur, N Gray, E Grosskreutz, J Jardel, CG Kachanov, M Kuhle, J Lamari, F Maceski, A del Mar Amador, M Mayer, B Morelli, C Petri, S Poesen, K Raaphorst, J Salachas, F Silani, V Turner, M Verbeek, MM Volk, AE Weishaupt, JH Weydt, P Ludolph, AC Otto, M |
author_sort | Steinacker, P |
collection | OXFORD |
description | <p><strong>Objective:</strong> Levels of chitotriosidase (CHIT1) are increased in the cerebrospinal fluid (CSF) of amyotrophic lateral sclerosis (ALS) patients reflecting microglial activation. Here, we determine the diagnostic and prognostic potential of CHIT1 for early symptomatic ALS.</p>
<p><strong>Methods:</strong> Overall, 275 patients from 8 European neurological centers were examined. We included ALS with <6 and >6 months from symptom onset, other motoneuron diseases (oMND), ALS mimics (DCon) and non-neurodegenerative controls (Con). CSF CHIT1 levels were analyzed for diagnostic power and association with progression and survival in comparison to the benchmark neurofilament. The 24-bp duplication polymorphism of CHIT1 was analyzed in a subset of patients (N=65).</p>
<p><strong>Results:</strong> Homozygous CHIT1 duplication mutation carriers (9%) invariably had undetectable CSF CHIT1 levels, while heterozygous carriers had similar levels as patients with wildtype CHIT1 (p=0.414). In both early and late symptomatic ALS CHIT1 levels was increased, did not correlate with patients’ progression rates, and was higher in patients diagnosed with higher diagnostic certainty. Neurofilament levels correlated with CHIT1 levels and prevailed over CHIT1 regarding diagnostic performance. Both CHIT1 and neurofilaments were identified as independent predictors of survival in late but not early symptomatic ALS. Evidence is provided that CHIT1 predicts progression in El Escorial diagnostic category in the group of ALS cases with a short duration.</p>
<p><strong>Conclusions:</strong> CSF CHIT1 level may have additional value in the prognostication of ALS patients with a short history of symptoms classified in diagnostic categories of lower clinical certainty. To fully interpret apparently low CHIT1 levels knowledge of CHIT1 genotype is needed.</p> |
first_indexed | 2024-03-06T20:37:12Z |
format | Journal article |
id | oxford-uuid:33091c35-c952-4d3f-b6f2-cd09c91b8776 |
institution | University of Oxford |
language | English |
last_indexed | 2024-03-06T20:37:12Z |
publishDate | 2021 |
publisher | Taylor and Francis |
record_format | dspace |
spelling | oxford-uuid:33091c35-c952-4d3f-b6f2-cd09c91b87762022-03-26T13:17:51ZChitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:33091c35-c952-4d3f-b6f2-cd09c91b8776EnglishSymplectic ElementsTaylor and Francis2021Steinacker, PFeneberg, EHalbgebauer, SWitzel, SVerde, FOeckl, PVan Damme, PGaur, NGray, EGrosskreutz, JJardel, CGKachanov, MKuhle, JLamari, FMaceski, Adel Mar Amador, MMayer, BMorelli, CPetri, SPoesen, KRaaphorst, JSalachas, FSilani, VTurner, MVerbeek, MMVolk, AEWeishaupt, JHWeydt, PLudolph, ACOtto, M<p><strong>Objective:</strong> Levels of chitotriosidase (CHIT1) are increased in the cerebrospinal fluid (CSF) of amyotrophic lateral sclerosis (ALS) patients reflecting microglial activation. Here, we determine the diagnostic and prognostic potential of CHIT1 for early symptomatic ALS.</p> <p><strong>Methods:</strong> Overall, 275 patients from 8 European neurological centers were examined. We included ALS with <6 and >6 months from symptom onset, other motoneuron diseases (oMND), ALS mimics (DCon) and non-neurodegenerative controls (Con). CSF CHIT1 levels were analyzed for diagnostic power and association with progression and survival in comparison to the benchmark neurofilament. The 24-bp duplication polymorphism of CHIT1 was analyzed in a subset of patients (N=65).</p> <p><strong>Results:</strong> Homozygous CHIT1 duplication mutation carriers (9%) invariably had undetectable CSF CHIT1 levels, while heterozygous carriers had similar levels as patients with wildtype CHIT1 (p=0.414). In both early and late symptomatic ALS CHIT1 levels was increased, did not correlate with patients’ progression rates, and was higher in patients diagnosed with higher diagnostic certainty. Neurofilament levels correlated with CHIT1 levels and prevailed over CHIT1 regarding diagnostic performance. Both CHIT1 and neurofilaments were identified as independent predictors of survival in late but not early symptomatic ALS. Evidence is provided that CHIT1 predicts progression in El Escorial diagnostic category in the group of ALS cases with a short duration.</p> <p><strong>Conclusions:</strong> CSF CHIT1 level may have additional value in the prognostication of ALS patients with a short history of symptoms classified in diagnostic categories of lower clinical certainty. To fully interpret apparently low CHIT1 levels knowledge of CHIT1 genotype is needed.</p> |
spellingShingle | Steinacker, P Feneberg, E Halbgebauer, S Witzel, S Verde, F Oeckl, P Van Damme, P Gaur, N Gray, E Grosskreutz, J Jardel, CG Kachanov, M Kuhle, J Lamari, F Maceski, A del Mar Amador, M Mayer, B Morelli, C Petri, S Poesen, K Raaphorst, J Salachas, F Silani, V Turner, M Verbeek, MM Volk, AE Weishaupt, JH Weydt, P Ludolph, AC Otto, M Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study |
title | Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study |
title_full | Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study |
title_fullStr | Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study |
title_full_unstemmed | Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study |
title_short | Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study |
title_sort | chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis a multicenter study |
work_keys_str_mv | AT steinackerp chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT feneberge chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT halbgebauers chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT witzels chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT verdef chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT oecklp chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT vandammep chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT gaurn chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT graye chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT grosskreutzj chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT jardelcg chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT kachanovm chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT kuhlej chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT lamarif chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT maceskia chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT delmaramadorm chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT mayerb chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT morellic chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT petris chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT poesenk chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT raaphorstj chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT salachasf chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT silaniv chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT turnerm chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT verbeekmm chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT volkae chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT weishauptjh chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT weydtp chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT ludolphac chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy AT ottom chitotriosidaseasbiomarkerforearlystageamyotrophiclateralsclerosisamulticenterstudy |